HT
ADVM

HAP Trading’s Adverum Biotechnologies ADVM Stock Holding History

HAP Trading’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,060
Closed -$1K – 2171
2021
Q4 		$1K Sell
2,060
-90
-4% -$1.8K ﹤0.01% 2428
2021
Q3 		$3K Buy
2,150
+290
+16% +$7.4K ﹤0.01% 2244
2021
Q2 		$11K Buy
+1,860
New +$100K ﹤0.01% 1963

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HAP Trading's ADVM Position: Q4 2019 in Review

HAP Trading sold out of Adverum Biotechnologies (ADVM) in Q4 2019, closing a stake of 7,319 shares — an estimated $399K sold.

HAP Trading first reported a position in ADVM in Q3 2019 and held it in 1 quarter. The position peaked at $399K in Q3 2019. 116 funds tracked by Wall St. Rank hold ADVM as of Q4 2019.

  • HAP Trading reported no remaining Adverum Biotechnologies position as of Q4 2019 after selling out during the quarter.
  • HAP Trading sold 7,319 Adverum Biotechnologies shares in Q4 2019, an estimated $399K.
  • HAP Trading first reported a position in Adverum Biotechnologies in Q3 2019 and held it in 1 quarter.
  • HAP Trading's Adverum Biotechnologies position peaked at $399K in Q3 2019.
  • 116 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2019.

Based on HAP Trading's 13F filing for Q4 2019, filed 11 Feb 2020.